|
2025 Conference Publication Selective inhibition of PI3Kp110a enhances chemotherapy efficacy by suppressing hepatic stellate cell activation in liver cancerLiang, X., Ruan, Q., Kim, M., Yang, H., Bridle, K. and Crawford, D. (2025). Selective inhibition of PI3Kp110a enhances chemotherapy efficacy by suppressing hepatic stellate cell activation in liver cancer. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Berlin, Germany, 17 - 21 October 2025. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/j.annonc.2025.10.194 |
|
2024 Conference Publication Chemotherapeutic drugs induce hepatic stellate cell activation in hepatocellular carcinoma via ROS-dependent PI3K pathwayRuan, Qi, Cao, Lu, Yang, Haotian, Burke, Leslie, Bridle, Kim, Crawford, Darrell and Liang, Xiaowen (2024). Chemotherapeutic drugs induce hepatic stellate cell activation in hepatocellular carcinoma via ROS-dependent PI3K pathway. The Liver Meeting, San Diego, CA, United States, 15 - 19 November 2024. Philadelphia, PA, United States: Wolters Kluwer Health. |
|
2023 Conference Publication Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancerRuan, Qi, Cao, Lu, Yang, Haotian, Burke, Leslie, Bridle, Kim, Crawford, Darrell and Liang, Xiaowen (2023). Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancer. EASL Congress 2023, Vienna, Austria, 21 - 24 June 2023. Amsterdam, Netherlands: Elsevier. |
